These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 29386513)

  • 1. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
    DeWaal D; Nogueira V; Terry AR; Patra KC; Jeon SM; Guzman G; Au J; Long CP; Antoniewicz MR; Hay N
    Nat Commun; 2018 Jan; 9(1):446. PubMed ID: 29386513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.
    Dai W; Wang F; Lu J; Xia Y; He L; Chen K; Li J; Li S; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Abudumijiti H; Chen R; Zhang R; Zhou L; Zhou Z; Zhu R; Yang J; Wang C; Zhang H; Zhou Y; Xu L; Guo C
    Oncotarget; 2015 May; 6(15):13703-17. PubMed ID: 25938543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells.
    Li M; Jin R; Wang W; Zhang T; Sang J; Li N; Han Q; Zhao W; Li C; Liu Z
    Oncotarget; 2017 Apr; 8(15):24777-24784. PubMed ID: 28445971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
    Shen YC; Ou DL; Hsu C; Lin KL; Chang CY; Lin CY; Liu SH; Cheng AL
    Br J Cancer; 2013 Jan; 108(1):72-81. PubMed ID: 23257894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
    Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
    Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
    Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway.
    Wu H; Pan L; Gao C; Xu H; Li Y; Zhang L; Ma L; Meng L; Sun X; Qin H
    Molecules; 2019 May; 24(10):. PubMed ID: 31137633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
    Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
    FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.
    Li S; Li J; Dai W; Zhang Q; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Mo W; Xu L; Guo C
    Br J Cancer; 2017 Nov; 117(10):1518-1528. PubMed ID: 28926527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
    Siddharth S; Kuppusamy P; Wu Q; Nagalingam A; Saxena NK; Sharma D
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
    Xu S; Herschman HR
    Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
    Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2.
    Xu D; Jin J; Yu H; Zhao Z; Ma D; Zhang C; Jiang H
    J Exp Clin Cancer Res; 2017 Mar; 36(1):44. PubMed ID: 28320429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.